



17 August 2018

### **EQUITIES**

1836 HK Price (at 13:00, 16 Aug 2018 GMT)	O	utperform HK\$8.27
Valuation - PER	HK\$	13.00
12-month target	HK\$	13.00
Upside/Downside	%	+57.2
12-month TSR	%	+62.6
Volatility Index	Lo	w/Medium
GICS sector Consumer Durables & Appare	el	
Market cap	HK\$m	6,570
Market cap	US\$m	837
Free float	%	56
30-day avg turnover	US\$m	0.3
Number shares on issue	m	794.4

#### Investment fundamentals

Year end 31 Dec		2017A	2018E	2019E	2020E
Revenue	m	1,577.3	1,569.0	1,648.6	1,763.9
EBIT	m	63.5	60.0	90.3	103.9
EBIT growth	%	-27.3	-5.5	50.4	15.1
Reported profit	m	62.6	56.0	87.5	100.7
Adjusted profit	m	62.6	56.0	87.5	100.7
EPS rep	¢	7.9	7.1	11.0	12.7
EPS rep growth	%	-23.3	-10.4	56.1	15.2
EPS adj	¢	7.9	7.1	11.0	12.7
EPS adj growth	%	-23.3	-10.4	56.1	15.2
PER rep	Х	13.3	14.9	9.5	8.3
PER adj	Х	13.3	14.9	9.5	8.3
Total DPS	¢	7.7	4.7	7.7	0.0
Total div yield	%	7.3	4.5	7.3	0.0
ROA	%	5.3	5.0	7.6	8.7
ROE	%	6.4	5.8	9.1	10.5
EV/EBITDA	Х	7.5	7.6	5.6	5.1
Net debt/equity	%	-7.4	-6.8	-6.8	-6.8
P/BV	Х	0.9	0.9	0.9	0.9

### 1836 HK rel HSI performance, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, August 2018 (all figures in USD unless noted, TP in HKD)

### Macquarie Governance and Risk Score (MGRS)

On our proprietary <u>Governance and Risk Score</u> Stella International Holdings scores in the third quartile of our current universe coverage.

#### **Analysts**

Macquarie Capital Limited



Linda Huang, CFA +852 3922 4068 linda.huang@macquarie.com

Hugo Shen +86 21 2412 9077 hugo.shen@macquarie.com

Hong Kong

# **Stella International Holdings**Adjusted OPM picking up

# **Key points**

- Shipment volume growth maintained while ASP continued to drop.
- Redundancy cost to reach ~US\$20m for FY18 and FY19; potential idle asset disposal.
- Financial position capable to support dividend policy.

#### **Event**

Stella released 1H18 results after market close. Revenue declined 3% YoY to US\$739m, while net profit dropped 19.6% YoY to US\$23m due to one-off redundancy expense and FX impact. Excluding the one-off items and impact from RMB appreciation, adjusted net profit would have grown 14.2% YoY. We lower our net profit by 11.4% and 1.1% for FY18E/19E. Maintain Outperform with an unchanged TP of HK\$13/sh based on 15x FY19E PER, factoring in Macquarie Macro Strategy's FX projection of US\$ appreciation.

#### **Impact**

- Shipment volume growth maintained while ASP continued to drop. Total shipment volume rose 7.4% YoY to 29m pairs in 1H18. The company maintained its guidance of 60mn pairs for full-year shipments. Meanwhile, ASP for footwear products fell 6.4% to US\$24.9 per pair, which was mainly due to style changes, according to management. The company believes that the ASP drop will continue but with limited impact on their margin recovery. They still expect OPM to reach 6% for FY18 and target 8% for the long term. During 1H18, the adjusted OPM improved 0.9ppt YoY to 5.7%.
- Redundancy cost to reach ~US\$20m for FY18 and FY19; potential idle asset disposal. Redundancy cost amounted to US\$7.5m in 1H18. The company expects another one-off charge of ~US\$15m from planned factory closure in Guangxi in 2H18 and estimates redundancy cost to be US\$20m in FY19. We believe the redundancy cost can be offset by potential land asset disposals next year (Dongguang idle land market value at US\$29m, with US\$8.5m book value). Stella is shifting capacity out of China and expects a 40:60 capacity split between China and overseas in 2019.
- Financial position capable to support dividend policy. Management is comfortable with the debt level, as most of their debt is short-term working capital borrowing. Regarding the client bankruptcy impact, the entire amount due from Rockport has been fully settled. As for Nine West, total outstanding receivables were ~US\$7m, with Stella's net exposure ~US\$4.5m deducting insurance coverage. As of 31 June 2018, Stella's total provision against receivables was US\$8.1m, which would be sufficient to cover the impairment loss. The company declared an interim dividend of HK\$30 cents/sh. Management expects operating cash flow to turn to a positive level at the end of the year, which could be capable of supporting their dividend policy.

# Earnings and target price revision

• We lower our net profit by 11.4% and 1.1% for FY18E/19E. TP remains unchanged at HK\$13/sh.

## Price catalyst

- 12-month price target: HK\$13.00 based on a PER methodology.
- · Catalyst: 3Q18 operation result

# **Action and recommendation**

Maintain Outperform.

# Investment thesis: Maintain Outperform, TP remains at HK\$13/sh

We maintain our Outperform rating on Stella International Holdings with an unchanged target price of HK\$13. We lower our NP estimates for FY18E/19E by 11.4% and 1.1% respectively, factoring in 1H18 results and management guidance.

Despite the ASP drop, we believe OPM will gradually recover, backed by efficiency improvements. We believe redundancy cost can be offset by potential land asset disposals next year.

Fig 1 PER band





Fig 2 Dividend yield band



Source: Bloomberg, Macquarie Research, August 2018

# **Earnings revision**

We lower our NP forecast for FY18E and FY19E by 11.4% and 1.1%, respectively, as we factor in 1H18 results and management guidance.

- **OP margin.** We raise our OP margin assumption by 1.3ppt for FY18 and 1.1ppt for FY19.
- Net margin. We lower our Net margin assumption by 0.4ppt for FY18 to factor in one-off cost.

Fig 3 Earnings revision summary

(US\$ mn)	Old FY18	Old FY19	New FY18	New FY19	% chg. FY18	% chg. FY19
Assumptions						
SSSg	4.0%	3.0%	-1.0%	3.0%	-5.0%	0.0%
OEM volume growth (%)	7.0%	5.0%	7.2%	5.0%	0.2%	0.0%
OEM ASP change (%)	-2.0%	5.0%	-5.6%	0.3%	-3.6%	-4.7%
Revenue	1,601	1,764	1,569	1,649	-2.0%	-6.6%
Gross Profit	282	327	271	292	-3.8%	-10.7%
Operating Profit	56	78	62	76	12.4%	-2.5%
Pre-Tax	65	90	60	90	-7.0%	-0.2%
Net Income	63	88	56	87	-11.4%	-1.1%
EPS (US\$)	7.98	11.15	7.07	11.03	-11.3%	-1.0%
Margin (%)						
Gross Margin	17.1%	17.6%	17.3%	17.7%	0.2ppt	0.1ppt
OP Margin	2.7%	3.5%	4.0%	4.6%	1.3ppt	1.1ppt
Net Margin	3.9%	4.4%	3.6%	5.3%	-0.4ppt	0.9ppt
Source: Macquarie Research, A	ugust 2018					

# **Macquarie Quant View**

The Quant View page below has been derived from models that are developed and maintained by Sales and Trading personnel at Macquarie. The models are not a product of the Macquarie Research Department.


The quant model currently holds a marginally positive view on Stella International Holdings. The strongest style exposure is Quality, indicating this stock is likely to have a superior and more stable underlying earnings stream. The weakest style exposure is Profitability, indicating this stock is not efficiently converting investments to earnings; proxied by ratios like ROE or ROA.



Global rank in Consumer Durables & Apparel

% of BUY recommendations 20% (1/5)

Number of Price Target downgrades 1 Number of Price Target upgrades 0




Displays where the company's ranked based on the fundamental consensus Price Target and Macquarie's Quantitative Alpha model.

Two rankings: Local market (Hong Kong) and Global sector (Consumer Durables & Apparel)


# **Macquarie Alpha Model ranking**

A list of comparable companies and their Macquarie Alpha model score (higher is better).




## **Factors driving the Alpha Model**

For the comparable firms this chart shows the key underlying styles and their contribution to the current overall Alpha score.



# **Macquarie Earnings Sentiment Indicator**

The Macquarie Sentiment Indicator is an enhanced earnings revisions signal that favours analysts who have more timely and higher conviction revisions. Current score shown below.




## **Drivers of Stock Return**

Breakdown of 1 year total return (local currency) into returns from dividends, changes in forward earnings estimates and the resulting change in earnings multiple.




# What drove this Company in the last 5 years

Which factor score has had the greatest correlation with the company's returns over the last 5 years.



# How it looks on the Alpha model

A more granular view of the underlying style scores that drive the alpha (higher is better) and the percentile rank relative to the sector and market.



Source (all charts): FactSet, Thomson Reuters, and Macquarie Quant. For more details on the Macquarie Alpha model or for more customised analysis and screens, please contact the Macquarie Global Quantitative/Custom Products Group (<a href="mailto:cpg@macquarie.com">cpg@macquarie.com</a>).

2017A

m

m m m

m

75

429 172 12

2019E

65

342 205 24

2018E

65

342 205 24

2020E

65

342 205 24

Interim Results		1H/18A	2H/18E	1H/19E	2H/19E	Profit & Loss		2017A	2018E	2019E	2020E
Revenue	m	739	830	778	871	Revenue	m	1,577	1,569	1,649	1,764
Gross Profit	m	122	150	133	159	Gross Profit	m	270	271	292	317
Cost of Goods Sold	m	617	680	645	712	Cost of Goods Sold	m	1,307	1,298	1,356	1,447
EBITDA	m	47	53	59	78	EBITDA	m	101	99	136	152
Depreciation	m	20	20	23	23	Depreciation	m	37	39	46	48
Amortisation of Goodwill	m	0	0	0	0	Amortisation of Goodwill	m	0	0	0	(
Other Amortisation	m	0	0	0	0	Other Amortisation	m	0	0	0	(
EBIT	m	27	33	36	54	EBIT	m	63	60	90	104
Net Interest Income	m	-1	-1	0	0	Net Interest Income	m	-1	-3	0	(
Associates	m	3	0	0	0	Associates	m	1	3	0	(
Exceptionals	m	0	0	0	0	Exceptionals	m	0	0	0	(
Forex Gains / Losses	m	0	0	0	0	Forex Gains / Losses	m	0	0	0	(
Other Pre-Tax Income	m	0	0	0	0	Other Pre-Tax Income	m	0	0	0	(
Pre-Tax Profit	m	28	32	36	54	Pre-Tax Profit	m	64	60	90	104
Tax Expense	m	-5	-2	-4	-4	Tax Expense	m	-4	-7	-7	-8
Net Profit	m	24	29	32	51	Net Profit	m	60	53	83	95
Minority Interests	m	1	2	1	3	Minority Interests	m	2	3	5	
Reported Earnings Adjusted Earnings	m m	25 25	31 31	34 34	54 54	Reported Earnings Adjusted Earnings	m m	63 63	56 56	87 87	10 <sup>-</sup>
,											
EPS (rep)	¢	3.1	3.9	4.2	6.8	EPS (rep)	¢	7.9	7.1	11.0	12.
EPS (adj)	¢	3.1	3.9	4.2	6.8	EPS (adj)	¢	7.9	7.1	11.0	12.7
EPS Growth yoy (adj)	%	-12.9	-8.4	35.5	72.5	EPS Growth (adj)	%	-23.3	-10.4	56.1	15.2
						PE (rep)	Х	13.3	14.9	9.5	8.3
						PE (adj)	Х	13.3	14.9	9.5	8.3
EBITDA Margin	%	6.3	6.3	7.6	8.9	Total DPS	¢	7.7	4.7	7.7	0.0
EBIT Margin	%	3.7	4.0	4.6	6.3	Total Div Yield	%	7.3	4.5	7.3	0.0
Earnings Split	%	44.2	55.8	38.4	61.6	Basic Shares Outstanding	m	793	793	793	793
Revenue Growth	%	-3.0	1.8	5.2	4.9	Diluted Shares Outstanding	m	793	793	793	793
EBIT Growth	%	-12.1	0.9	31.8	65.7						
Profit and Loss Ratios		2017A	2018E	2019E	2020E	Cashflow Analysis		2017A	2018E	2019E	2020E
Revenue Growth	%	1.7	-0.5	5.1	7.0	EBITDA	m	101	99	136	152
EBITDA Growth	%	-22.2	-1.4	37.2	11.7	Tax Paid	m	-4	-7	-7	-8
	%	-27.3	-5.5	50.4	15.1	Chas in Working Cap		20	-2	-2	-2
EBIT Growth							m			0	(
Gross Profit Margin	%	17.1	17.3	17.7	18.0	Net Interest Paid	m m	-1	-3	0	
Gross Profit Margin EBITDA Margin	%	17.1 6.4	17.3 6.3	8.3	18.0 8.6	Net Interest Paid Other	m m	-1 1	28	-11	-25
Gross Profit Margin EBITDA Margin EBIT Margin	% % %	17.1 6.4 4.0	17.3 6.3 3.8	8.3 5.5	18.0 8.6 5.9	Net Interest Paid Other Operating Cashflow	m m <b>m</b>	-1 1 <b>118</b>	28 <b>116</b>	-11 <b>116</b>	-25 <b>11</b> 6
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin	% % %	17.1 6.4 4.0 4.0	17.3 6.3 3.8 3.6	8.3 5.5 5.3	18.0 8.6 5.9 5.7	Net Interest Paid Other Operating Cashflow Acquisitions	m m <b>m</b> m	-1 1 <b>118</b> 0	28 <b>116</b> 0	-11 <b>116</b> 0	-25 <b>116</b> (
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio	% % % %	17.1 6.4 4.0 4.0 98.0	17.3 6.3 3.8 3.6 66.8	8.3 5.5 5.3 69.9	18.0 8.6 5.9 5.7 0.0	Net Interest Paid Other Operating Cashflow Acquisitions Capex	m m m m m	-1 1 <b>118</b> 0 -50	28 <b>116</b> 0 -45	-11 <b>116</b> 0 -45	-25 <b>116</b> ( -45
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio EV/EBITDA	% % % % %	17.1 6.4 4.0 4.0 98.0 7.5	17.3 6.3 3.8 3.6 66.8 7.6	8.3 5.5 5.3 69.9 5.6	18.0 8.6 5.9 5.7 0.0 5.1	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales	m m m m m	-1 1 <b>118</b> 0 -50	28 <b>116</b> 0 -45	-11 <b>116</b> 0 -45	-25 <b>116</b> ( -45
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin	% % % %	17.1 6.4 4.0 4.0 98.0	17.3 6.3 3.8 3.6 66.8	8.3 5.5 5.3 69.9	18.0 8.6 5.9 5.7 0.0	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales Other	m m m m m m	-1 1 118 0 -50 0	28 <b>116</b> 0 -45 0	-11 <b>116</b> 0 -45 0	-25 <b>116</b> ( -45 (
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio EV/EBITDA EV/EBIT	% % % % %	17.1 6.4 4.0 4.0 98.0 7.5	17.3 6.3 3.8 3.6 66.8 7.6	8.3 5.5 5.3 69.9 5.6	18.0 8.6 5.9 5.7 0.0 5.1	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales Other Investing Cashflow	m m m m m m m	-1 1 118 0 -50 0 -50	28 116 0 -45 0 1	-11 116 0 -45 0 1	-25 116 ( -45 ( 1
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio EV/EBITDA EV/EBIT  Balance Sheet Ratios	% % % % x x	17.1 6.4 4.0 4.0 98.0 7.5 11.9	17.3 6.3 3.8 3.6 66.8 7.6 12.3	8.3 5.5 5.3 69.9 5.6 8.5	18.0 8.6 5.9 5.7 0.0 5.1 7.4	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales Other Investing Cashflow Dividend (Ordinary)	m m m m m m m	-1 1 118 0 -50 0 -50 -71	28 116 0 -45 0 1 -44 -61	-11 116 0 -45 0 1 -44 -61	-25 116 ( -45 ( -44 -6
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio EV/EBITDA EV/EBIT  Balance Sheet Ratios ROE	% % % % x x	17.1 6.4 4.0 4.0 98.0 7.5 11.9	17.3 6.3 3.8 3.6 66.8 7.6 12.3	8.3 5.5 5.3 69.9 5.6 8.5	18.0 8.6 5.9 5.7 0.0 5.1 7.4	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales Other Investing Cashflow Dividend (Ordinary) Equity Raised	m m m m m m m m	-1 1 118 0 -50 0 0 -50 -71	28 116 0 -45 0 1 -44 -61	-11 116 0 -45 0 1 -44 -61	-25 116 ( -45 ( -44 -6
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio EV/EBITDA EV/EBITDA EV/EBIT  Balance Sheet Ratios ROE ROA	% % % % x x	17.1 6.4 4.0 98.0 7.5 11.9	17.3 6.3 3.8 3.6 66.8 7.6 12.3	8.3 5.5 5.3 69.9 5.6 8.5	18.0 8.6 5.9 5.7 0.0 5.1 7.4	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales Other Investing Cashflow Dividend (Ordinary) Equity Raised Debt Movements	m m m m m m m m m	-1 118 0 -50 0 -50 -71 0	28 116 0 -45 0 1 -44 -61 0	-11 116 0 -45 0 1 -44 -61 0	-2! 110 ( -4! ( -4- -6- (
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio EV/EBITDA EV/EBIT  Balance Sheet Ratios ROE ROA ROIC	% % % % x x	17.1 6.4 4.0 4.0 98.0 7.5 11.9 6.4 5.3 6.7	17.3 6.3 3.8 3.6 66.8 7.6 12.3	8.3 5.5 5.3 69.9 5.6 8.5	18.0 8.6 5.9 5.7 0.0 5.1 7.4	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales Other Investing Cashflow Dividend (Ordinary) Equity Raised Debt Movements Other	m m m m m m m m m	-1 1 1188 0 -50 0 0 -50 -71 0 0	28 116 0 -45 0 1 -44 -61 0 0	-11 116 0 -45 0 1 -44 -61 0	-2! 110 (-4! (-4- -4- -6- (-6- (-6- (-6- (-6-)
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio EV/EBITDA EV/EBIT  Balance Sheet Ratios ROE ROA ROIC Net Debt/Equity	% % % % x x x	17.1 6.4 4.0 98.0 7.5 11.9 6.4 5.3 6.7 -7.4	17.3 6.3 3.8 3.6 66.8 7.6 12.3 5.8 5.0 5.9	8.3 5.5 5.3 69.9 5.6 8.5 9.1 7.6 9.3 -6.8	18.0 8.6 5.9 5.7 0.0 5.1 7.4 10.5 8.7 10.7 -6.8	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales Other Investing Cashflow Dividend (Ordinary) Equity Raised Debt Movements	m m m m m m m m m	-1 118 0 -50 0 -50 -71 0	28 116 0 -45 0 1 -44 -61 0	-11 116 0 -45 0 1 -44 -61 0	-25 116 (-45 (-44 -6 (-6)
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio EV/EBITDA EV/EBIT  Balance Sheet Ratios ROE ROA ROIC Net Debt/Equity Interest Cover	% % % % x x * * * * * *	17.1 6.4 4.0 98.0 7.5 11.9 6.4 5.3 6.7 -7.4 64.7	17.3 6.3 3.8 3.6 66.8 7.6 12.3 5.8 5.0 5.9 -6.8 23.5	8.3 5.5 5.3 69.9 5.6 8.5 9.1 7.6 9.3 -6.8 nmf	18.0 8.6 5.9 5.7 0.0 5.1 7.4 10.5 8.7 10.7 -6.8 nmf	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales Other Investing Cashflow Dividend (Ordinary) Equity Raised Debt Movements Other Financing Cashflow	m m m m m m m m m m m	-1 118 0 -50 0 -50 -71 0 0 -1 -72	28 116 0 -45 0 1 -44 -61 0 0	-11 116 0 -45 0 1 -44 -61 0 0	-25 116 (-45 () 1 -44 -61 () ()
Gross Profit Margin EBITDA Margin EBIT Margin Net Profit Margin Payout Ratio EV/EBITDA EV/EBIT  Balance Sheet Ratios	% % % % x x x	17.1 6.4 4.0 98.0 7.5 11.9 6.4 5.3 6.7 -7.4	17.3 6.3 3.8 3.6 66.8 7.6 12.3 5.8 5.0 5.9	8.3 5.5 5.3 69.9 5.6 8.5 9.1 7.6 9.3 -6.8	18.0 8.6 5.9 5.7 0.0 5.1 7.4 10.5 8.7 10.7 -6.8	Net Interest Paid Other Operating Cashflow Acquisitions Capex Asset Sales Other Investing Cashflow Dividend (Ordinary) Equity Raised Debt Movements Other	m m m m m m m m m	-1 1 1188 0 -50 0 0 -50 -71 0 0	28 116 0 -45 0 1 -44 -61 0 0	-11 116 0 -45 0 1 -44 -61 0	-25 116 0 -45 0 1 1 -44 -61 0 0 0 0

0 0 552 **1,188** 0 0 552 **1,188** Intangibles Other Assets Total Assets m m **m** 0 540 0 552 1,228 1,188 Payables Short Term Debt Long Term Debt Provisions Other Liabilities 182 0 0 0 51 **233** 961 -6 0 **954 1,188** 182 0 0 0 51 146 0 182 0 m m m m 3 0 111 51 233 961 -6 0 954 1,188 **Total Liabilities** 260 233 961 -6 0 **954 1,188** Shareholders' Funds Minority Interests 972 -4 0 m m m Total S/H Equity
Total Liab & S/H Funds 968 1,228 m m All figures in USD unless noted. Source: Company data, Macquarie Research, 八月 2018

**Balance Sheet** 

Receivables

Inventories Investments

Fixed Assets

Cash

17 August 2018 5

## Important disclosures:

#### **Recommendation definitions**

#### Macquarie - Australia/New Zealand

Outperform – return >3% in excess of benchmark return Neutral – return within 3% of benchmark return Underperform – return >3% below benchmark return

Benchmark return is determined by long term nominal GDP growth plus 12 month forward market dividend yield, which is currently around 9%.

#### Macquarie - Asia/Europe

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

## Mazi Macquarie - South Africa

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

#### Macquarie - Canada

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

#### Macquarie - USA

Outperform (Buy) – return >5% in excess of Russell 3000 index return

Neutral (Hold) – return within 5% of Russell 3000 index return

Underperform (Sell)– return >5% below Russell 3000 index return

## Volatility index definition\*

This is calculated from the volatility of historical price movements.

**Very high-highest risk** – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.

**High** – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

**Medium** – stock should be expected to move up or down at least 30–40% in a year.

**Low-medium** – stock should be expected to move up or down at least 25–30% in a year.

**Low** – stock should be expected to move up or down at least 15–25% in a year.

\* Applicable to Asia/Australian/NZ/Canada stocks

Recommendations - 12 months

**Note:** Quant recommendations may differ from Fundamental Analyst recommendations

#### Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

**EPS** = adjusted net profit / efpowa\*

ROA = adjusted ebit / average total assets
ROA Banks/Insurance = adjusted net profit /average
total assets

ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation \*equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

#### Recommendation proportions - For quarter ending 30 June 2018

	AU/NZ	Asia	RSA	USA	CA	EUR	
Outperform	52.87%	61.26%	48.86%	47.54%	69.86%	46.61%	(for global coverage by Macquarie, 3.51% of stocks followed are investment banking clients)
Neutral	34.10%	27.25%	36.36%	46.72%	21.92%	43.22%	(for global coverage by Macquarie, 2.10% of stocks followed are investment banking clients)
Underperform	13.03%	11.49%	14.77%	5.74%	8.22%	10.17%	(for global coverage by Macquarie, 0.00% of stocks followed are investment banking clients)



(all figures in HKD currency unless noted)

Note: Recommendation timeline – if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, August 2018

#### 12-month target price methodology

1836 HK: HK\$13.00 based on a PER methodology

### Company-specific disclosures:

Important disclosure information regarding the subject companies covered in this report is available at <a href="www.macquarie.com/research/disclosures">www.macquarie.com/research/disclosures</a>.

Date	Stock Code (BBG code)	Recommendation	Target Price
16-Mar-2018	1836 HK	Outperform	HK\$13.00
14-Sep-2017	1836 HK	Outperform	HK\$16.00
18-Aug-2017	1836 HK	Outperform	HK\$14.40
02-Aug-2017	1836 HK	Outperform	HK\$14.50
21-Mar-2017	1836 HK	Outperform	HK\$13.80
17-Mar-2017	1836 HK	Outperform	HK\$12.50
17-Feb-2017	1836 HK	Outperform	HK\$13.50
20-Oct-2016	1836 HK	Outperform	HK\$16.00
27-Aug-2016	1836 HK	Neutral	HK\$11.70
17-Jun-2016	1836 HK	Neutral	HK\$16.40
19-Jan-2016	1836 HK	Outperform	HK\$21.00
29-Aug-2015	1836 HK	Outperform	HK\$22.00

#### Target price risk disclosures:

**1836 HK:** Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

# Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views

Macquarie Research Stella International Holdings

expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities.

#### General disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Mazi Macquarie Securities (RF) (Pty) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FCA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Members of the Macro Strategy team are Sales & Trading personnel who provide desk commentary that is not a product of the Macquarie Research department or subject to FINRA Rule 2241 or any other regulation regarding independence in the provision of equity research.

Country-specific disclaimers: Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organization of the Australian Securities Exchange. Macquarie Securities (Australia) Limited staff involved with the preparation of research have regular interaction with companies they cover. Additionally, Macquarie Group Limited does and seeks to do business with companies covered by Macquarie Research. There are robust information barriers in place to protect the independence of Macquarie Research's product. However, recipients of Macquarie Research should be aware of this potential conflict of interest. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. Canada: In Canada, research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd., a (i) member of the Investment Industry Regulatory Organization of Canada and the Canadian Investor Protection Fund, and (ii) participating organization of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. This research is distributed in the United States, as third party research by Macquarie Capital Markets North America Ltd., which is a registered broker-dealer and member of Financial Industry Regulatory Authority and the Securities Investor Protection Corporation. Macquarie Capital Markets North America Ltd. accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd. in the United States and sent to US persons. Any US person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd. should do so with Macquarie Capital Markets North America Ltd. This research is intended for distribution in the United States only to major Institutional Investors (as such term is defined in SEC 15a-6 and Section 15 of the Securities Exchange Act of 1934, as amended) and is not intended for the use of any person or entity that is not a major institutional investor. Research analysts of Macquarie Capital Markets Canada Ltd. are not registered/qualified as research analysts with FINRA. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd. is to allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Germany: In Germany, this research is issued and/or distributed by Macquarie Capital (Europe) Limited, Niederlassung Deutschland, which is authorised and regulated by the UK Financial Conduct Authority (No. 193905), and in Germany by BaFin. France. In France, research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India: In India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 463469-W) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. The recipient of this report shall not engage in any activities which may give rise to potential conflicts of interest to the report. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Macquarie may be in past one year or now being an Issuer of Structured Warrants on securities mentioned in this report. Thailand: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thaiiod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=MDIS03002001000000&serviceId=SDIS03002 001000. South Africa: In South Africa, research is issued and distributed by Mazi Macquarie Securities (RF) (Pty) Ltd, a member of the JSE Limited. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (Europe) Limited, Macquarie Capital Markets Canada Ltd, Mazi Macquarie Securities (RF) (Pty) Ltd and Macquarie Capital (USA) Inc. represent and

Macquarie Research Stella International Holdings

warrant that they are institutional investors as defined in the Securities and Futures Act. **United States**: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc. affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at <a href="https://www.macquarie.com/research/disclosures">www.macquarie.com/research/disclosures</a>, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019.

© Macquarie Group



## **Equities**

# **Asia Research**

## **Head of Equity Research**

Jake Lynch (Asia – Head)	(852) 3922 3583
Hiroyuki Sakaida (Japan – Head)	(813) 3512 6695
Conrad Werner (ASEAN – Head)	(65) 6601 0182

#### Automobiles, Auto Parts

 Janet Lewis (China, Japan)
 (813) 3512 7856

 Allen Yuan (China)
 (8621) 2412 9009

 James Hong (Korea)
 (822) 3705 8661

 Amit Mishra (India)
 (9122) 6720 4084

#### **Banks and Financials**

Scott Russell (Asia) (852) 3922 3567 Dexter Hsu (China, Taiwan) (8862) 2734 7530 Keisuke Moriyama (Japan) (813) 3512 7476 Chan Hwang (Korea) (822) 3705 8643 Suresh Ganapathy (India) (9122) 6720 4078 Jayden Vantarakis (Indonesia) (6221) 2598 8310 Anand Pathmakanthan (Malaysia) (603) 2059 8833 Gilbert Lopez (Philippines) (632) 857 0892 Ken Ang (Singapore) Peach Patharavanakul (Thailand) (65) 6601 0836 (662) 694 7753

#### **Basic Materials, Commodities**

David Ching (China, Hong Kong)	(852) 3922 1823
Yasuhiro Nakada (Japan)	(813) 3512 7862
Anna Park (Korea)	(822) 3705 8669
Sumangal Nevatia (India)	(9122) 6720 4093
Jayden Vantarakis (Indonesia)	(6221) 2598 8310
Farrah Aqlima (Malaysia)	(603) 2059 8987

#### Conglomerates

 David Ng (China, Hong Kong)
 (852) 3922 1291

 Gilbert Lopez (Philippines)
 (632) 857 0892

 Conrad Werner (Singapore)
 (65) 6601 0182

## Consumer, Gaming

(852) 3922 4068 Linda Huang (Asia) Zibo Chen (China, Hong Kong) (852) 3922 1130 (852) 3922 3581 (852) 3922 3768 Terence Chang (China, Hong Kong) Sunny Chow (China, Hong Kong) Stella Li (China, Taiwan) (8862) 2734 7514 Leon Rapp (Japan) (813) 3512 7879 Kwang Cho (Korea) (822) 3705 4953 Amit Sinha (India) (9122) 6720 4085 Robert Pranata (Indonesia) (6221) 2598 8366 Richardo Walujo (Indonesia) (6221) 2598 8369 Denise Soon (Malaysia) (603) 2059 8845 Karisa Magpayo (Philippines) (632) 857 0899 Chalinee Congmuang (Thailand) (662) 694 7993

## **Emerging Leaders**

 Jake Lynch (Asia)
 (852) 3922 3583

 Kwang Cho (Korea)
 (822) 3705 4953

 Corinne Jian (Greater China)
 (8862) 2734 7522

 Conrad Werner (ASEAN)
 (65) 6601 0182

 Bo Denworalak (Thailand)
 (662) 694 7774

#### Infrastructure, Industrials, Transportation

 Patrick Dai (China)
 (8621) 2412 9082

 Eric Zong (China, Hong Kong)
 (852) 3922 4749

 Kunio Sakaida (Japan)
 (813) 3512 7873

 James Hong (Korea)
 (822) 3705 8661

 Corinne Jian (Taiwan)
 (8862) 2734 7522

 Inderjeetsingh Bhatia (India)
 (9122) 6720 4087

 Azita Nazrene (ASEAN)
 (65) 6601 0560

#### Internet, Media and Software

Wendy Huang (Asia) (852) 3922 3378 Marcus Yang (Greater China) (8862) 2734 7532 Alankar Garude (India) (9122) 6720 4134

#### Oil, Gas and Petrochemicals

Aditya Suresh (Asia) (852) 3922 1265 Anna Park (Asia) (822) 3705 8669 Yasuhiro Nakada (Japan) (813) 3512 7862 Corinne Jian (Taiwan) (8862) 2734 7522 Ben Shane Lim (Malaysia) (603) 2059 8868 Yupapan Polpornprasert (Thailand) (662) 694 7729

#### Pharmaceuticals and Healthcare

 David Ng (China, Hong Kong)
 (852) 3922 1291

 Xiang Gao (China, Hong Kong)
 (8621) 2412 9006

 Corinne Jian (China)
 (8862) 2734 7522

 Alankar Garude (India)
 (9122) 6720 4134

 Richardo Walujo (Indonesia)
 (6221) 259 88 369

## Property, REIT

Tuck Yin Soong (Asia, Singapore) (65) 6601 0838 David Ng (China, Hong Kong) . (852) 3922 1291 (852) 3922 1181 (813) 3512 7476 Kelvin Tam (China) Keisuke Morivama (Japan) Tomoyoshi Omuro (Japan) (813) 3512 7474 Abhishek Bhandari (India) (9122) 6720 4088 Richard Danusaputra (Indonesia) (6221) 2598 8368 Aiman Mohamad (Malaysia) (603) 2059 8986 (632) 857 0893 Kervin Sisayan (Philippines) Bo Denworalak (Thailand) (662) 694 7774

## **Technology**

Damian Thong (Asia, Japan) (813) 3512 7877 Allen Chang (Greater China) (852) 3922 1136 Jeffrey Ohlweiler (Greater China) (8862) 2734 7512 Chris Yu (Greater China) (8621) 2412 9024 Kaylin Tsai (Greater China) (8862) 2734 7523 Lynn Luo (Greater China) (8862) 2734 7534 (8862) 2734 7515 Patrick Liao (Greater China) Verena Jeng (Greater China) (852) 3922 3766 Daniel Kim (Korea) (822) 3705 8641 (9122) 6720 4088 (603) 2059 8987 Abhishek Bhandari (India) Farrah Aqlima (Malaysia)

#### **Telecoms**

 Allen Chang (Greater China)
 (852) 3922 1136

 Prem Jearajasingam (ASEAN)
 (603) 2059 8989

 Nathania Nurhalim (Indonesia)
 (6221) 2598 8365

 Kervin Sisayan (Philippines)
 (632) 857 0893

#### **Utilities, Renewables**

 Hiroyuki Sakaida (Japan)
 (813) 3512 6695

 Patrick Dai (China)
 (8621) 2412 9082

 Inderjeetsingh Bhatia (India)
 (9122) 6720 4087

 Karisa Magpayo (Philippines)
 (632) 857 0899

## Strategy, Country

Viktor Snvets (Asia, Global)
David Ng (China, Hong Kong)
Hiroyuki Sakaida (Japan)
Chan Hwang (Korea)
Jeffrey Ohlweiler (Taiwan)
Inderjeetsingh Bhatia (India)
Conrad Werner (ASEAN, Singapore)
Jayden Vantarakis (Indonesia)
Anand Pathmakanthan (Malaysia)
Gilbert Lopez (Philippines)
Peach Patharavanakul (Thailand)

## Find our research at

Macquarie: www.macquarieresearch.com Thomson: www.thomson.com/financial Reuters: www.knowledge.reuters.com Bloomberg: MAC GO

Factset: http://www.factset.com/home.aspx CapitalIQ www.capitaliq.com

Email macresearch@macquarie.com for access

# **Asia Sales**

#### Regional Heads of Sales

Miki Edelman (Global) (1 212) 231 6121 Amelia Mehta (Asia) (65) 6601 0211 Jeffrey Shiu (China, Hong Kong) (852) 3922 2061 Sandeep Bhatia (India) (9122) 6720 4101 (41 22) 818 7712 Thomas Renz (Geneva) (813) 3512 7823 Tomohiro Takahashi (Japan) John Jay Lee (Korea) (822) 3705 9988 Nik Hadi (Malaysia) (603) 2059 8888 Gino C Rojas (Philippines) (632) 857 0861

#### Regional Heads of Sales cont'd

 Paul Colaco (San Francisco)
 (1 415) 762 5003

 Angus Kent (Thailand)
 (662) 694 7601

 Ben Musgrave (UK/Europe)
 (44 20) 3037 4882

 Christina Lee (UK/Europe)
 (44 20) 3037 4873

## **Sales Trading**

Adam Zaki (Asia) (852) 3922 2002 Stanley Dunda (Indonesia) (6221) 515 1555

#### Sales Trading cont'd

Suhaida Samsudin (Malaysia)
Michael Santos (Philippines)
Chris Reale (New York)
Marc Rosa (New York)
Justin Morrison (Singapore)
Daniel Clarke (Taiwan)
Brendan Rake (Thailand)
Mike Keen (UK/Europe)

(603) 2059 8888 (632) 857 0813 (1 212) 231 2555 (1 212) 231 2555 (65) 6601 0288 (8862) 2734 7580 (662) 694 7707 (44 20) 3037 4905